Study Hza114971, A Multicentre Randomised, Double-Blind, Placebo-Contr
Research payments
$2,124,715
Through program year 2021, $2,124,715 in research payments was reported against Study Hza114971, A Multicentre Randomised, Double-Blind, Placebo-Contr, across 182 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $342,268 | 36 |
| 2020 | Research | $994,796 | 65 |
| 2019 | Research | $787,651 | 81 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Jeffrey Hirschfield St Petersburg, FL Named on 38 payments
- David Miller Clairton, PA Named on 12 payments
- Humberto Fernandez Miro Miami, FL Named on 12 payments
- Karen Dunn Raleigh, NC Named on 10 payments
- Armando Acevedo Miami, FL Named on 9 payments
- Maria Cubillas Homestead, FL Named on 9 payments
- Michael Maloney Gainesville, GA Named on 8 payments
- Ana Acosta Miami, FL Named on 8 payments
- Rafael Cardenas Miami, FL Named on 8 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.